Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches
暂无分享,去创建一个
Shadma Parveen | Mohd Rehan | A. Abuzenadah | G. Damanhouri | M. A. Beg | M. S. Jamal | M. Suhail | S. Parveen | A. Chaudhary | M. Rehan | Ghazi A. Damanhouri | Adel M. Abuzenadah | Mohammad S. Jamal | Mohd A. Beg | Mohd Suhail | Adeel G. A. Chaudhary | Shadma Parveen
[1] D. Knighton,et al. Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. , 2010, ACS medicinal chemistry letters.
[2] G. Russo. Ins and outs of dietary phytochemicals in cancer chemoprevention. , 2007, Biochemical pharmacology.
[3] P. Srinivas,et al. Structure activity relationship of plumbagin in BRCA1 related cancer cells , 2013, Molecular carcinogenesis.
[4] Kaushik Raha,et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. , 2010, ACS medicinal chemistry letters.
[5] Renxiao Wang,et al. Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.
[6] Aamir Ahmad,et al. Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. , 2012, Bioorganic & medicinal chemistry letters.
[7] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[8] P. Kuo,et al. Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Induces Apoptosis and Cell Cycle Arrest in A549 Cells through p53 Accumulation via c-Jun NH2-Terminal Kinase-Mediated Phosphorylation at Serine 15 in Vitro and in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.
[9] P. Yue,et al. Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.
[10] N. Udupa,et al. Niosomal Plumbagin with Reduced Toxicity and Improved Anticancer Activity in BALB/C Mice , 1996, The Journal of pharmacy and pharmacology.
[11] Aris Persidis,et al. Cancer multidrug resistance , 1999, Nature Biotechnology.
[12] John Calvin Reed. Promise and problems of Bcl-2 antisense therapy. , 1997, Journal of the National Cancer Institute.
[13] Michael Karin,et al. NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.
[14] N. Jing,et al. Targeting Stat3 in cancer therapy. , 2005, Anti-cancer drugs.
[15] P. Workman,et al. Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors , 2011, Current medicinal chemistry.
[16] Michael Karin,et al. The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.
[17] John Calvin Reed,et al. Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. , 2010, Journal of medicinal chemistry.
[18] James B. Mitchell,et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. , 2004, Cancer research.
[19] J. Baell,et al. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. , 2002, Biochemical pharmacology.
[20] Zhiwei Wang,et al. Plumbagin‐induced apoptosis of human breast cancer cells is mediated by inactivation of NF‐κB and Bcl‐2 , 2008, Journal of cellular biochemistry.
[21] J M Thornton,et al. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.
[22] S. Morimoto,et al. Construction and expression of specificity-improved single-chain variable fragments against the bioactive naphthoquinone, plumbagin. , 2009, Biological & pharmaceutical bulletin.
[23] C. Sardet,et al. Post-activation Turn-off of NF-κB-dependent Transcription Is Regulated by Acetylation of p65* , 2003, The Journal of Biological Chemistry.
[24] S. Dasgupta,et al. A spectroscopic investigation into the interactions of 3′‐O‐carboxy esters of thymidine with bovine serum albumin , 2009, Biopolymers.
[25] L. O’Neill,et al. Studies into the Effect of the Tyrosine Kinase Inhibitor Herbimycin A on NF-κB Activation in T Lymphocytes EVIDENCE FOR COVALENT MODIFICATION OF THE p50 SUBUNIT (*) , 1995, The Journal of Biological Chemistry.
[26] S. Srinivasula,et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] B. Aggarwal,et al. Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-κB Activation and NF-κB-regulated Gene Products Through Modulation of p65 and IκBα Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents* , 2006, Journal of Biological Chemistry.
[28] K. Ye. PIKE/nuclear PI 3‐kinase signaling in preventing programmed cell death , 2005, Journal of cellular biochemistry.
[29] Aamir Ahmad,et al. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. , 2009, Mutagenesis.
[30] B. Stanley,et al. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2007 .
[31] B. Aggarwal,et al. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Sardet,et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. , 2003, The Journal of biological chemistry.
[33] C. Lindsley,et al. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2007, Current topics in medicinal chemistry.
[34] S. Becker,et al. Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.
[35] Todd J. A. Ewing,et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..
[36] Li Yang,et al. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. , 2009, Journal of medicinal chemistry.
[37] S. Joos,et al. The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.
[38] Massimo Libra,et al. Akt as a therapeutic target in cancer. , 2008, Expert opinion on therapeutic targets.
[39] Didier Devaurs,et al. MoMA-LigPath: a web server to simulate protein–ligand unbinding , 2013, Nucleic Acids Res..
[40] Bipul R. Acharya,et al. The natural naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the microtubule network through tubulin binding. , 2008, Biochemistry.
[41] Michael Karin,et al. NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.
[42] Masakazu Toi,et al. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.
[43] M. Krishnaswamy,et al. Plumbagin: A study of its anticancer, antibacterial & antifungal properties. , 1980, Indian journal of experimental biology.
[44] Jing Ma,et al. A Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation* , 2003, Journal of Biological Chemistry.
[45] T. Tsai,et al. Plumbagin, Isolated from Plumbago zeylanica, Induces Cell Death through Apoptosis in Human Pancreatic Cancer Cells , 2010, Pancreatology.
[46] B. Aggarwal,et al. 5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization , 2010, Molecular Cancer Research.
[47] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[48] James B. Mitchell,et al. Nuclear Factor-κB is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma , 2004, Cancer Research.
[49] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[50] Huan Yang,et al. The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.
[51] Kam Y. J. Zhang,et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.
[52] Y. Ben-Neriah,et al. NF-kappaB inhibition: a double-edged sword in cancer? , 2006, European journal of cancer.
[53] H. J. Kim,et al. NF-κB and IKK as therapeutic targets in cancer , 2006, Cell Death and Differentiation.
[54] G. Srinivas,et al. Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] R. Sarkar,et al. Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinoma in vivo and Leishmania donovani Promastigotes in vitro , 2002, Phytotherapy research : PTR.
[56] I. Enyedy,et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.
[57] J. Turkson,et al. STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.
[58] B. Aggarwal,et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. , 2006, The Journal of biological chemistry.
[59] Luhua Lai,et al. Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..
[60] A. Martelli,et al. Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? , 2006, Cellular signalling.
[61] H. J. Kim,et al. NF-kappaB and IKK as therapeutic targets in cancer. , 2006, Cell death and differentiation.
[62] G. Dewson,et al. Bcl-2 family-regulated apoptosis in health and disease , 2010 .
[63] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[64] Thierry Siméon,et al. A path planning approach for computing large-amplitude motions of flexible molecules , 2005, ISMB.
[65] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[66] K. Kinzler,et al. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.
[67] B. Hellman,et al. Genotoxicity of plumbagin and its effects on catechol and NQNO-induced DNA damage in mouse lymphoma cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[68] M. A. Akbarsha,et al. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. , 2008, Anticancer research.
[69] P. Sachdanandam,et al. Effect of plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma , 1993, Molecular and Cellular Biochemistry.
[70] S. Korsmeyer,et al. Cell Death Critical Control Points , 2004, Cell.
[71] M. Toi,et al. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.
[72] Z. Nikolovska-Coleska,et al. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review , 2012, Expert opinion on therapeutic patents.
[73] L. Johnson,et al. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 , 1997, Nature Structural Biology.
[74] S. Korsmeyer,et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. , 2004, Cancer cell.
[75] S. Agrawal,et al. Inhibition of Lysine Acetyltransferase KAT3B/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, Plumbagin* , 2009, The Journal of Biological Chemistry.
[76] M. Aziz,et al. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. , 2008, Cancer research.
[77] Y. Shih,et al. Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase‐2 and urokinase‐ plasminogen activator , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.
[78] A. Gillum,et al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. , 2002, Antisense & nucleic acid drug development.
[79] N. Varin‐Blank,et al. A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line , 2012, Molecular Cancer.
[80] Y. Ben-Neriah,et al. NF-κB inhibition: A double-edged sword in cancer? , 2006 .
[81] Roger L. Williams,et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.
[82] N. Udupa,et al. Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. , 1997, Indian journal of physiology and pharmacology.
[83] Shivendra V. Singh,et al. Plumbagin-induced Apoptosis in Human Prostate Cancer Cells is Associated with Modulation of Cellular Redox Status and Generation of Reactive Oxygen Species , 2008, Pharmaceutical Research.
[84] A. Baldwin,et al. Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[85] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[86] Roman A. Laskowski,et al. LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..
[87] D. Alessi,et al. Use of Akt Inhibitor and a Drug-resistant Mutant Validates a Critical Role for Protein Kinase B/Akt in the Insulin-dependent Regulation of Glucose and System A Amino Acid Uptake* , 2008, Journal of Biological Chemistry.
[88] T. Tanaka,et al. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. , 1998, Cancer letters.
[89] P. Kuo,et al. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. , 2008, Cancer letters.
[90] A. E. Rogers,et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.
[91] P. Kuo,et al. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells , 2006, Molecular Cancer Therapeutics.
[92] Ximing Xu,et al. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway , 2012, Journal of Biosciences.
[93] Suneet Shukla,et al. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2 , 2007, Molecular Cancer Therapeutics.
[94] Mary K Joseph,et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.
[95] B. Rayet,et al. Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.
[96] P. Black,et al. In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human Glioblastomas , 2004, Clinical Cancer Research.